Research programme: tyrosine kinase inhibitors - MannKind/The Leukemia & Lymphoma Society

Drug Profile

Research programme: tyrosine kinase inhibitors - MannKind/The Leukemia & Lymphoma Society

Latest Information Update: 01 May 2012

Price : $50

At a glance

  • Originator MannKind Corporation; The Leukemia & Lymphoma Society
  • Class
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported T cell lymphoma; T cell prolymphocytic leukaemia

Most Recent Events

  • 01 May 2012 No development reported for T-cell prolymphocytic leukaemia in USA (unspecified route)
  • 01 May 2012 No development reported for T-cell lymphoma in USA (unspecified route)
  • 05 May 2008 Early research in T-cell prolymphocytic leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top